Kyowa Kirin Co., Ltd. (TYO:4151)
2,403.50
-26.50 (-1.09%)
Sep 4, 2026, 3:30 PM JST
Kyowa Kirin Revenue
Kyowa Kirin had revenue of 145.16B JPY in the quarter ending June 30, 2026, with 15.27% growth. This brings the company's revenue in the last twelve months to 529.80B, up 7.41% year-over-year. In the year 2025, Kyowa Kirin had annual revenue of 496.83B with 0.26% growth.
Revenue (ttm)
529.80B
Revenue Growth
+7.41%
P/S Ratio
2.38
Revenue / Employee
102.65M
Employees
5,161
Market Cap
1.26T
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 496.83B | 1.27B | 0.26% |
| Dec 31, 2024 | 495.56B | 53.33B | 12.06% |
| Dec 31, 2023 | 442.23B | 43.86B | 11.01% |
| Dec 31, 2022 | 398.37B | 46.13B | 13.09% |
| Dec 31, 2021 | 352.25B | 33.89B | 10.65% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Tsuruha Holdings | 1.81T |
| MatsukiyoCocokara & Co. | 1.13T |
| COSMOS Pharmaceutical | 1.10T |
| Sugi Holdings | 1.04T |
| Sundrug | 850.15B |
| Ain Holdings | 647.83B |
| Kusuri No Aoki Holdings | 566.87B |
| Create SD Holdings | 497.13B |
Kyowa Kirin News
- 3 days ago - Kyowa Kirin Agrees To Measures Aimed At Reducing U.S. Medicine Costs - Nasdaq
- 3 days ago - Kyowa Kirin To Lower Cost Of Medicines For American Patients; U.S. To Defer Section 232 Tariffs - Nasdaq
- 3 days ago - Trump Administration Reaches Drug Pricing Deals With 9 Companies - WSJ
- 4 weeks ago - Kyowa Kirin Quarterly report: Q2 2026 - Filings
- 4 weeks ago - Kyowa Kirin Slides: Q2 2026 - Filings
- 2 months ago - The XLH Network and Kyowa Kirin Launch the XLH Community Guidebook to Help People Navigate Lifelong Journey with XLH - GlobeNewsWire
- 2 months ago - Kyowa Kirin to Present New Complementary Evidence Further Defining Clinical Utility of Mogamulizumab in Cutaneous T-Cell Lymphoma at 2026 WCCL - GlobeNewsWire
- 3 months ago - Kura, Kyowa Kirin to present updated frontline data from Phase 1 KOMET-007 trial - TheFly